- In September 2022, Polyplus, a prominent provider of upstream solutions for biologic and cell and gene therapy, expanded its mRNA support portfolio. The launch of in vivo-jetRNA+ transfection reagent enhances in vivo mRNA delivery with a preformed liposome. This addition signifies Polyplus' commitment to advancing efficient and precise transfection methods in the field of gene therapy
- In February 2022, Mirus Bio, a key player in delivery solutions under Gamma Biosciences, launched the TransIT-VirusGEN SELECT Transfection Kits. Specifically designed for large-scale viral vector production, these kits cater to the demands of cell and gene therapy applications, showcasing Mirus Bio's commitment to advancing efficient and scalable transfection solutions in the biotechnology industry
- In August 2021, Mirus Bio, a prominent player in transfection technologies, launched viral vector transfection kits tailored for cell and gene therapy manufacturing. These specialized transfection reagents aim to optimize the delivery of packaging and transfer vector DNA to suspension, enhancing the production of recombinant adeno-associated virus AAV) and lentivirus LV) vectors
- In November 2020, Thermo Fisher Scientific Inc. partnered with Northeastern University, enhancing innovation in the biopharmaceutical industry, particularly in gene and cell therapies. By consistently developing advanced reagents and techniques, the collaboration aimed to bolster sensitivity and accuracy in experiments and drug development, contributing to the production of valuable and efficient tools crucial for the transfection process
